Uncovering a novel potential target in non-alcoholic fatty liver disease

被引：0
|
作者：
Praestholm, Stine Marie [1 ]
Correia, Jorge [1 ]
Ruas, Jorge [1 ]
机构：
[1] Karolinska Inst, Physiol & pharmacol, Stockholm, Sweden
来源：
JOURNAL OF HEPATOLOGY | 2023年 / 78卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
WED-409
引用
收藏
页码：S741 / S741
页数：1
相关论文
共 50 条
  • [21] Non-alcoholic fatty liver disease
    Sattar, Naveed
    Forrest, Ewan
    Preiss, David
    BMJ-BRITISH MEDICAL JOURNAL, 2014, 349
  • [22] Non-alcoholic fatty liver disease
    Li, Wenhao
    Alazawi, William
    CLINICAL MEDICINE, 2020, 20 (05) : 509 - 512
  • [23] The potential of flavonoids in the treatment of non-alcoholic fatty liver disease
    Van De Wier, Bregje
    Koek, Ger H.
    Bast, Aalt
    Haenen, Guido R. M. M.
    CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION, 2017, 57 (04) : 834 - 855
  • [24] Parental non-alcoholic fatty liver disease increases risk of non-alcoholic fatty liver disease in offspring
    Long, Michelle T.
    Gurary, Ellen B.
    Massaro, Joseph M.
    Ma, Jiantao
    Hoffmann, Udo
    Chung, Raymond T.
    Benjamin, Emelia J.
    Loomba, Rohit
    LIVER INTERNATIONAL, 2019, 39 (04) : 740 - 747
  • [25] The immune response as a therapeutic target in non-alcoholic fatty liver disease
    Ortiz-Lopez, Nicolas
    Fuenzalida, Catalina
    Soledad Dufeu, Maria
    Pinto-Leon, Araceli
    Escobar, Alejandro
    Poniachik, Jaime
    Pablo Roblero, Juan
    Valenzuela-Perez, Lucia
    Beltran, Caroll J.
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [26] What is the (right) target for non-alcoholic fatty liver disease (NAFLD)?
    Huber, Yvonne
    Galle, Peter R.
    Schattenberg, Joern M.
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2020, 58 (01): : 68 - 73
  • [27] Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
    Eslami, Layli
    Merat, Shahin
    Malekzadeh, Reza
    Nasseri-Moghaddam, Siavosh
    Aramin, Hermineh
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2013, (12):
  • [28] PCSK7: A novel regulator of apolipoprotein B and a potential target against non-alcoholic fatty liver disease
    Sachan, Vatsal
    Le Devehat, Mailys
    Roubtsova, Anna
    Essalmani, Rachid
    Laurendeau, Jean-Francois
    Garcon, Damien
    Susan-Resiga, Delia
    Duval, Stephanie
    Mikaeeli, Sahar
    Hamelin, Josee
    Evagelidis, Alexandra
    Chong, Michael
    Pare, Guillaume
    Chernetsova, Elizabeta
    Gao, Zu-Hua
    Robillard, Isabelle
    Ruiz, Matthieu
    Trinh, Vincent Quoc-Huy
    Estall, Jennifer L.
    Faraj, May
    Austin, Richard C.
    Sauvageau, Martin
    Prat, Annik
    Kiss, Robert S.
    Seidah, Nabil G.
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2024, 150
  • [29] Implicating ISOC1 as a Novel Molecular Target in Non-Alcoholic Fatty Liver Disease
    Marger, Fabrice
    Delangre, Etienne
    Schaer, Tifany
    Negro, Francesco
    Clement-Leboube, Sophie
    Spahr, Laurent
    Foti, Michelangelo
    Goossens, Nicolas
    SWISS MEDICAL WEEKLY, 2023, 153 : 19S - 19S
  • [30] Unlocking the Therapeutic Potential of Ellagic Acid for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis
    Senavirathna, Tharani
    Shafaei, Armaghan
    Lareu, Ricky
    Balmer, Lois
    ANTIOXIDANTS, 2024, 13 (04)
12345